Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia

Amir T. Fathi; Eytan M. Stein; Courtney D. DiNardo; Mark J. Levis; Pau Montesinos; Stéphane de Botton

doi:10.1002/ajh.26142

Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia

Amir T. Fathi, Eytan M. Stein, Courtney D. DiNardo, Mark J. Levis, Pau Montesinos, Stéphane de Botton

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

17 Citations (Scopus)

Résumé

Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarely necessitates interruption or discontinuation of AML therapy.

langue originale	Anglais
Pages (de - à)	735-746
Nombre de pages	12
journal	American Journal of Hematology
Volume	96
Numéro de publication	6
Les DOIs	https://doi.org/10.1002/ajh.26142
état	Publié - 1 juin 2021

Accès au document

10.1002/ajh.26142

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{6de6f6e5e2ba42b6948f9efa50726811,

title = "Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia",

abstract = "Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarely necessitates interruption or discontinuation of AML therapy.",

author = "Fathi, {Amir T.} and Stein, {Eytan M.} and DiNardo, {Courtney D.} and Levis, {Mark J.} and Pau Montesinos and {de Botton}, St{\'e}phane",

note = "Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC.",

year = "2021",

month = jun,

day = "1",

doi = "10.1002/ajh.26142",

language = "English",

volume = "96",

pages = "735--746",

journal = "American Journal of Hematology",

issn = "0361-8609",

number = "6",

}

TY - JOUR

T1 - Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia

AU - Fathi, Amir T.

AU - Stein, Eytan M.

AU - DiNardo, Courtney D.

AU - Levis, Mark J.

AU - Montesinos, Pau

AU - de Botton, Stéphane

PY - 2021/6/1

Y1 - 2021/6/1

N2 - Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarely necessitates interruption or discontinuation of AML therapy.

AB - Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarely necessitates interruption or discontinuation of AML therapy.

UR - http://www.scopus.com/inward/record.url?scp=85102636513&partnerID=8YFLogxK

U2 - 10.1002/ajh.26142

DO - 10.1002/ajh.26142

M3 - Review article

C2 - 33625753

AN - SCOPUS:85102636513

SN - 0361-8609

VL - 96

SP - 735

EP - 746

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 6

ER -